Table 1.
Distribution of characteristics related to demographics and medical history, by vaccine status. All women were unvaccinated at the baseline, and they can contribute with person-time to more than one vaccine status group
| Covariates | Baseline (all unvaccinated) (n=2 946 448) |
At least one dose (n=2 580 007) | At least two doses (n=2 515 868) | Three doses and more (n=1 652 472) |
|---|---|---|---|---|
| Age, median (IQR) | 44 (24-58) | 46 (25-59) | 46 (26-59) | 53 (41-63) |
| Employed as a healthcare worker: | ||||
| No | 2 018 128 (68.5) | 1 740 484 (67.5) | 1 690 984 (67.2) | 1 057 348 (64.0) |
| Yes | 928 320 (31.5) | 839 523 (32.5) | 824 884 (32.8) | 595 124 (36.0) |
| Country of birth: | ||||
| Sweden | 2 383 529 (80.9) | 2 153 373 (83.5) | 2 107 976 (83.8) | 1 432 112 (86.7) |
| Outside Sweden | 562 919 (19.1) | 426 634 (16.5) | 407 892 (16.2) | 220 360 (13.3) |
| Education: | ||||
| Primary | 416 303 (14.1) | 354 647 (13.7) | 342 635 (13.6) | 204 655 (12.4) |
| Secondary | 1 076 764 (36.5) | 957 364 (37.1) | 940 376 (37.4) | 689 049 (41.7) |
| Tertiary | 1 077 071 (36.6) | 989 890 (38.4) | 978 262 (38.9) | 743 930 (45) |
| Unknown | 376 310 (12.8) | 278 106 (10.8) | 254 595 (10.1) | 14 838 (0.9) |
| Cardiovascular disease: | ||||
| No | 2 850 349 (96.7) | 2 491 633 (96.6) | 2 428 912 (96.5) | 1 580 841 (95.7) |
| Yes | 96 099 (3.3) | 88 374 (3.4) | 86 956 (3.5) | 71 631 (4.3) |
| Stroke or transient ischaemic attack: | ||||
| No | 2 927 167 (99.3) | 2 562 162 (99.3) | 2 498 227 (99.3) | 1 637 146 (99.1) |
| Yes | 19 281 (0.7) | 17 845 (0.7) | 17 641 (0.7) | 15 326 (0.9) |
| Diabetes (type 1 and 2): | ||||
| No | 2 835 636 (96.2) | 2 477 521 (96.0) | 2 414 737 (96.0) | 1 568 459 (94.9) |
| Yes | 110 812 (3.8) | 102 486 (4.0) | 101 131 (4.0) | 84 013 (5.1) |
| Chronic pulmonary disease: | ||||
| No | 2 928 408 (99.4) | 2 563 464 (99.4) | 2 499 620 (99.4) | 1 638 670 (99.2) |
| Yes | 18 040 (0.6) | 16 543 (0.6) | 16 248 (0.6) | 13 802 (0.8) |
| Asthma: | ||||
| No | 2 877 204 (97.6) | 2 518 549 (97.6) | 2 456 384 (97.6) | 1 615 853 (97.8) |
| Yes | 69 244 (2.4) | 61 458 (2.4) | 59 484 (2.4) | 36 619 (2.2) |
| Chronic kidney disease: | ||||
| No | 2 908 552 (98.7) | 2 546 491 (98.7) | 2 483 198 (98.7) | 1 629 523 (98.6) |
| Yes | 37 896 (1.3) | 33 516 (1.3) | 32 670 (1.3) | 22 949 (1.4) |
| Cancer: | ||||
| No | 2 886 227 (98.0) | 2 523 106 (97.8) | 2 459 511 (97.8) | 1 602 926 (97.0) |
| Yes | 60 221 (2.0) | 56 901 (2.2) | 56 357 (2.2) | 49 546 (3.0) |
| Coagulation disorders: | ||||
| No | 1 139 856 (99.2) | 1 038 321 (99.2) | 1 018 983 (99.2) | 702 468 (99.2) |
| Yes | 8821 (0.8) | 7890 (0.8) | 7717 (0.8) | 5634 (0.8) |
| Polycystic ovary syndrome: | ||||
| No | 1 139 698 (99.2) | 1 038 724 (99.3) | 1 019 459 (99.3) | 704 123 (99.4) |
| Yes | 8979 (0.8) | 7487 (0.7) | 7241 (0.7) | 3979 (0.6) |
| Thyroid diseases: | ||||
| No | 2 728 628 (92.6) | 2 380 747 (92.3) | 2 319 269 (92.2) | 1 494 707 (90.5) |
| Yes | 217 820 (7.4) | 199 260 (7.7) | 196 599 (7.8) | 157 765 (9.5) |
| Pituitary disorders: | ||||
| No | 1 142 025 (99.4) | 1 040 378 (99.4) | 1 020 982 (99.4) | 704 115 (99.4) |
| Yes | 6652 (0.6) | 5833 (0.6) | 5718 (0.6) | 3987 (0.6) |
| Uterine polyps or fibroids: | ||||
| No | 1 119 516 (97.5) | 1 020 167 (97.5) | 1 001 063 (97.5) | 688 302 (97.2) |
| Yes | 29 161 (2.5) | 26 044 (2.5) | 25 637 (2.5) | 19 800 (2.8) |
| Endometriosis: | ||||
| No | 913 984 (79.6) | 837 134 (80.0) | 821 956 (80.1) | 566 195 (80.0) |
| Yes | 234 693 (20.4) | 209 077 (20.0) | 204 744 (19.9) | 141 907 (20.0) |
| Pelvic inflammatory diseases: | ||||
| No | 1 052 420 (91.6) | 963 202 (92.1) | 946 222 (92.2) | 658 303 (93.0) |
| Yes | 96 257 (8.4) | 83 009 (7.9) | 80 478 (7.8) | 49 799 (7.0) |
| Obesity: | ||||
| No | 2 898 410 (98.4) | 2 537 952 (98.4) | 2 475 086 (98.4) | 1 624 829 (98.3) |
| Yes | 48 038 (1.6) | 42 055 (1.6) | 40 782 (1.6) | 27 643 (1.7) |
| Autoimmune diseases: | ||||
| No | 2 883 402 (97.9) | 2 522 085 (97.8) | 2 458 815 (97.7) | 1 606 176 (97.2) |
| Yes | 63 046 (2.1) | 57 922 (2.2) | 57 053 (2.3) | 46 296 (2.8) |
| Menopausal hormone: | ||||
| No | 910 720 (79.3) | 820 835 (78.5) | 803 415 (78.3) | 518 113 (73.2) |
| Yes | 237 957 (20.7) | 225 376 (21.5) | 223 285 (21.7) | 189 989 (26.8) |
| Contraception: | ||||
| No | 673 527 (58.6) | 611 978 (58.5) | 601 640 (58.6) | 465 248 (65.7) |
| Yes | 475 150 (41.4) | 434 233 (41.5) | 425 060 (41.4) | 242 854 (34.3) |
| Anticoagulants: | ||||
| No | 2 813 692 (95.5) | 2 455 434 (95.2) | 2 392 597 (95.1) | 1 544 641 (93.5) |
| Yes | 132 756 (4.5) | 124 573 (4.8) | 123 271 (4.9) | 107 831 (6.5) |
| Antidepressant treatment: | ||||
| No | 2 556 629 (86.8) | 2 222 691 (86.2) | 2 165 607 (86.1) | 1 397 733 (84.6) |
| Yes | 389 819 (13.2) | 357 316 (13.8) | 350 261 (13.9) | 254 739 (15.4) |
| Tranexamic acid: | ||||
| No | 1 137 176 (99.0) | 1 035 938 (99.0) | 1 016 703 (99.0) | 701 847 (99.1) |
| Yes | 11 501 (1.0) | 10 273 (1.0) | 9997 (1.0) | 6255 (0.9) |
| Oral corticosteroids: | ||||
| No | 2 810 256 (95.4) | 2 455 195 (95.2) | 2 393 249 (95.1) | 1 556 863 (94.2) |
| Yes | 136 192 (4.6) | 124 812 (4.8) | 122 619 (4.9) | 95 609 (5.8) |
| Epilepsy medication: | ||||
| No | 1 063 528 (92.6) | 969 199 (92.6) | 951 321 (92.7) | 651 465 (92.0) |
| Yes | 85 149 (7.4) | 77 012 (7.4) | 75 379 (7.3) | 56 637 (8.0) |
| NSAIDs: | ||||
| No | 801 144 (69.7) | 729 467 (69.7) | 715 586 (69.7) | 475 232 (67.1) |
| Yes | 347 533 (30.3) | 316 744 (30.3) | 311 114 (30.3) | 232 870 (32.9) |
| Numbers of specialist outpatient visits, median (IQR) | 1 (0-3) | 1 (0-3) | 1 (0-3) | 1 (0-3) |
| Days of inpatient stay, median (IQR) | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| Number of primary care visits, median (IQR) | 4 (1-12) | 4 (1-12) | 4 (1-13) | 5 (1-14) |
Data are number (percentage), unless otherwise stated. IQR=interquartile range; NSAIDs=Non-steroidal anti-inflammatory drugs.